#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize cannabinoid hyperemesis syndrome (CHS) as a serious adverse effect in regular cannabis users presenting with severe, refractory nausea and vomiting, as early identification can prevent unnecessary diagnostic workups and guide appropriate management through cannabis cessation. Understanding the role of the endocannabinoid system in nausea regulation helps explain why some patients experience a paradoxical worsening of symptoms despite using cannabis for symptom relief, allowing clinicians to counsel patients about dose-dependent risks and addiction potential. This recognition is critical for primary care and emergency medicine providers who frequently encounter patients with intractable nausea, as misdiagnosis delays appropriate treatment and patient education about cannabis
Cannabinoid hyperemesis syndrome (CHS), colloquially termed “scromiting” due to its severe combined screaming and vomiting episodes, represents a paradoxical clinical condition where chronic cannabis use triggers intractable nausea and vomiting despite initial symptom relief. The proposed mechanism involves dysregulation of the endocannabinoid system’s control over emetic pathways, with evidence suggesting a dose-dependent threshold effect where cumulative cannabinoid exposure overwhelms normal homeostatic mechanisms. CHS typically presents in heavy, long-term cannabis users and manifests in a cyclical pattern with acute episodes potentially requiring emergency department evaluation and IV hydration, though symptoms paradoxically resolve with cannabis cessation. Clinicians should maintain high suspicion for CHS in patients presenting with chronic vomiting who report regular cannabis use, as misdiagnosis often leads to unnecessary gastroenterologic workup and delayed recognition of the true etiology. The condition has become increasingly recognized as cannabis potency and availability have increased, making it an important differential diagnosis in contemporary practice. Patients with CHS should be counseled that complete abstinence from cannabis is the definitive treatment, and clinicians should educate chronic cannabis users about this emerging risk, particularly those using high-potency products or consuming daily.
“Cannabinoid Hyperemesis Syndrome is real and I see it regularly in my practice, but it’s almost entirely preventable through patient education about dosing thresholds and consumption patterns before someone develops this self-reinforcing cycle of heavy use and intractable vomiting.”
💊 Cannabinoid hyperemesis syndrome (CHS) remains an underrecognized but clinically significant condition, particularly as cannabis potency and frequency of use have increased substantially over the past decade. The proposed mechanism involving dysregulation of the endocannabinoid system’s role in nausea and vomiting control is biologically plausible, though the exact threshold dose, duration, or individual genetic susceptibility factors that precipitate CHS remain incompletely understood. Clinicians should maintain heightened suspicion for CHS in patients presenting with cyclic, intractable nausea and vomiting, particularly those with heavy cannabis use who have failed conventional antiemetic trials or whose symptoms paradoxically improve with hot showers or cessation of cannabis. Important confounders include the wide variability in cannabinoid concentrations across products, concurrent use of other substances, underlying gastrointestinal or psychiatric conditions, and
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: